期刊
NEPHROLOGY DIALYSIS TRANSPLANTATION
卷 17, 期 7, 页码 1170-1175出版社
OXFORD UNIV PRESS
DOI: 10.1093/ndt/17.7.1170
关键词
aluminium hyperphosphataemia; lanthanum; magnesium; renal bone disease; sevelamer hydrochloride
A historical look at research in hyperphosphataemia of chronic kidney disease over the last 40 years shows remarkable advances in our understanding of this abnormality and in the technology used to manage it, Phosphate binders, which have become a mainstay in the management of hyperphosphataemia, have evolved from the early use of aluminium gels to Calcium salts, to novel, non-absorbed. aluminium-free, calcium-free agents Such as sevelamer hydrochloride, and to magnesium, iron-, and lanthanum-based compounds. With recent advances, clinical management of this complication of chronic renal disease is evolving from adequate care to optimal care. such that new standards in phosphorous management are being set. and various parameters of patient care are being integrated to optimize outcomes and minimize side effects. This paper provides a historical view of the clinical management of hyperphosphataemia, and. looks to advances in treatment that are changing the course of renal bone disease management.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据